Zydus Lifesciences bags USFDA nod for ulcer drug Sucralfate
Ahmedabad: Pharma major, Zydus Lifesciences Limited, has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Sucralfate Tablets USP, 1 gram (USRLD: Carafate Tablets, 1 gram).
Sucralfate is used to treat and prevent ulcers in the intestines by forming a coating over ulcers, protecting the area from further injury. This helps ulcers heal more quickly.
The drug will be manufactured at the group’s topical manufacturing facility at SEZ, Ahmedabad (India).
Sucralfate Tablets USP, 1 gram had annual sales of USD 84 mn in the United States (IQVIA MAT Feb. 2023).
The group now has 367 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Lifesciences bags USFDA nod for Metronidazole topical cream to treat skin disorder
Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), an Indian Pharmaceutical company is a fully integrated, global healthcare provider. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.
Read also: Hypertension drug: Zydus Lifesciences gets USFDA approval for Metoprolol Tartrate Tablets
